Diagnostics

ITM Executes Option to In-license Targeted Radionuclide Therapy Candidate LuCaFab (ITM-31) for the Treatment of Malignant Brain Tumors

 Exclusive license from Helmholtz Munich will enable ITM to access IP and know-how to develop and commercialize ITM-31 for glioblastoma...

Plus Therapeutics Presents Preliminary Safety and Feasibility Data from ReSPECT-LM Clinical Trial at the European Association of Nuclear Medicine Congress

ReSPECT-LM Phase 1 clinical trial selected as TOP Trials Oral Presentation Treatment was well tolerated without dose limiting toxicities and...

Emory Healthcare Researcher Wins Two Awards Using Konica Minolta’s AI Analysis Tool With Dynamic Digital Radiography in Shoulder Pathology

KMHA Dynamic Digital Radiography - Shoulder Dynamic Digital Radiography enables the visualization of anatomy in motion, so clinicians can visualize...

F2G to Present Interim Results from Phase 2B Open Label Study of Olorofim in Invasive Fungal Infections at IDWeek 2022

MANCHESTER, United Kingdom, Oct. 13, 2022 (GLOBE NEWSWIRE) -- F2G Ltd, a clinical-stage biopharmaceutical company focused on the discovery and...

error: Content is protected !!